{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:30:18Z","timestamp":1792020618119,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Helmsley Charitable Trust and La Fondation pour la Recherche M\u00e9dicale","award":["FDM201806006069"],"award-info":[{"award-number":["FDM201806006069"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD), including Crohn\u2019s disease (CD) and ulcerative colitis (UC), remain heterogeneous disorders with variable response to biologics. Post-operative recurrence in CD is common despite surgery and prophylactic biotherapies. Understanding the inflammatory mediators associated with recurrence and treatment response could pave the way for personalized strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed serum inflammatory protein signatures using proteomics in two prospective cohorts. The REMIND cohort included post-operative CD patients undergoing ileocecal resection with endoscopic assessment at 6\u2009months (M6). Serum samples were collected at surgery and 6\u2009months later. The ELYP cohort consisted of active IBD patients starting new biotherapies (anti-tumor necrosis factor [anti-TNF], ustekinumab, or vedolizumab). Serum samples were collected pre- and post-treatment (Weeks 14 and 52).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the REMIND cohort, proteomic analysis revealed elevated levels of IFN-\u03b3, CXCL9, and MMP-10 in patients with recurrence, with concentrations associated with recurrence severity. Preoperative MMP-10 levels predicted severe recurrence (AUC\u2009=\u20090.70). Under biotherapies, treatment-specific proteins were associated with recurrence: CXCL9 for anti-TNF and OSM\/TGF\u03b1 modules for ustekinumab. In the ELYP cohort, IFN-\u03b3 and CXCL9 were significantly elevated in CD compared to UC and associated with disease activity. Early response to anti-TNF treatment (Week 14) was associated with reductions in CXCL9, MMP-10, and OSM, while deep remission (Week 52) correlated with decreases in CXCL9 and OSM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings reveal inflammatory blood proteomic signatures associated with post-operative recurrence and biologic treatment failure in IBD. Several key biomarkers were identified. These results support the rationale for personalized approaches, including combination therapies targeting multiple pathways.<\/jats:p>\n                    <jats:p>ClincialTrials.gov number, NCT02693340 and NCT02693340<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf162","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:46:32Z","timestamp":1756986392000},"source":"Crossref","is-referenced-by-count":5,"title":["Blood proteomic signatures associated with disease activity in inflammatory bowel diseases"],"prefix":"10.1093","volume":"19","author":[{"given":"Ma\u00ebva","family":"Veyssi\u00e8re","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM U976 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9273-9133","authenticated-orcid":false,"given":"Nassim","family":"Hammoudi","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, INSERM U1342, Institut de Recherche Saint-Louis , Paris,","place":["France"]},{"name":"Gastroenterology Department, AP-HP, H\u00f4pital Saint-Louis\/Lariboisi\u00e8re , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Le Bourhis","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, INSERM U1342, Institut de Recherche Saint-Louis , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9borah","family":"Hassid","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, AP-HP, H\u00f4pital Saint-Louis\/Lariboisi\u00e8re , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Bonnet","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, AP-HP, H\u00f4pital Saint-Louis\/Lariboisi\u00e8re , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My-Linh","family":"Tran Minh","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, AP-HP, H\u00f4pital Saint-Louis\/Lariboisi\u00e8re , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Baudry","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, AP-HP, H\u00f4pital Saint-Louis\/Lariboisi\u00e8re , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Gornet","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, AP-HP, H\u00f4pital Saint-Louis\/Lariboisi\u00e8re , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Chardiny","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, INSERM U1342, Institut de Recherche Saint-Louis , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Seksik","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CRSA, Sorbonne Universit\u00e9, INSERM, APHP, Paris Center for Microbiome Medicine (PaCeMM) FHU, Saint-Antoine Hospital , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Nancey","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHU de Lyon, Lyon-Sud hospital, Pierre-Benite, France and INSERM U1111-CIRI , Lyon,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hopitaux Universitaires Bic\u00eatre, AP-HP, Universit\u00e9 Paris Saclay, INSERM CESP , Le Kremlin Bic\u00eatre, Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Treton","sequence":"additional","affiliation":[{"name":"Paris IBD Center, Groupe hospitalier priv\u00e9 Ambroise-Pare Hartmann , Neuilly, 92200,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7684-6067","authenticated-orcid":false,"given":"Pauline","family":"Wils","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Claude Huriez hospital, University of Lille 2 , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-409X","authenticated-orcid":false,"given":"Anthony","family":"Buisson","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Clermont Auvergne, 3iHP, CHU Clermont-Ferrand, Service d\u2019H\u00e9pato- Gastroent\u00e9rologie, Inserm U1071, M2iSH, USC-INRA 2018 , Clermont-Ferrand,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Boureille","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, CHU Nantes, Institut des Maladies de l\u2019Appareil Digestif, Inserm CIC 1413 , Nantes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"H\u00e9buterne","sequence":"additional","affiliation":[{"name":"CHU de Nice et Universit\u00e9 C\u00f4te d\u2019Azur , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Serrero","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Marseille Nord, Assistance Publique-H\u00f4pitaux de Marseille (AP-HM), University of Aix-Marseille , Marseille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-2902","authenticated-orcid":false,"given":"Mathurin","family":"Fumery","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Amiens University Hospital et PeriTox, UMR I-01, Universit\u00e9 de Picardie Jules Verne , Amiens,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Louis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHU of Li\u00e8ge University Hospital , Liege,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanc","sequence":"additional","affiliation":[{"name":"Service d\u2019h\u00e9patogastroent\u00e9rologie B, Centre Hospitalier Universitaire (CHU) Montpellier et Universit\u00e9 de Montpellier , Montpellier,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Universit\u00e9 de Lorraine , Vand\u0153uvre-l\u00e8s-Nancy, F-54500,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Bezault","sequence":"additional","affiliation":[{"name":"REMIND Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1849-9834","authenticated-orcid":false,"given":"Vassili","family":"Soumelis","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM U976 , Paris,","place":["France"]},{"name":"Owkin France , Paris, 75010,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2012-7522","authenticated-orcid":false,"given":"Matthieu","family":"Allez","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, INSERM U1342, Institut de Recherche Saint-Louis , Paris,","place":["France"]},{"name":"Gastroenterology Department, AP-HP, H\u00f4pital Saint-Louis\/Lariboisi\u00e8re , Paris,","place":["France"]},{"name":"Department of Microbiology and Immunology, McGill University , Montreal, Quebec,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"2025102819160550300_jjaf162-B1","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2025102819160550300_jjaf162-B2","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2025102819160550300_jjaf162-B3","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"2025102819160550300_jjaf162-B4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/J.GASTRO.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"2025102819160550300_jjaf162-B5","doi-asserted-by":"publisher","first-page":"e1003348","DOI":"10.1371\/JOURNAL.PMED.1003348","article-title":"Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: a prospective multicohort study of the ABIRISK consortium","volume":"17","author":"H\u00e4ssler","year":"2020","journal-title":"PLoS Med"},{"key":"2025102819160550300_jjaf162-B6","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/nejmoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"New Engl J Med"},{"key":"2025102819160550300_jjaf162-B7","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"New Engl J Med"},{"key":"2025102819160550300_jjaf162-B8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"New Engl J Med"},{"key":"2025102819160550300_jjaf162-B9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"New Engl J Med"},{"key":"2025102819160550300_jjaf162-B10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/gut.26.2.146","article-title":"Prognosis in Crohn\u2019s disease\u2014based on results from a regional patient group from the county of Copenhagen","volume":"26","author":"Binder","year":"1985","journal-title":"Gut"},{"key":"2025102819160550300_jjaf162-B11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/gut.2004.045294","article-title":"Impact of the increasing use of immunosuppressants in Crohn\u2019s disease on the need for intestinal surgery","volume":"54","author":"Cosnes","year":"2005","journal-title":"Gut"},{"key":"2025102819160550300_jjaf162-B12","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/ajg.2012.298","article-title":"Surgery in a population-based cohort of Crohn\u2019s disease from Olmsted County, Minnesota (1970\u20132004)","volume":"107","author":"Peyrin-Biroulet","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2025102819160550300_jjaf162-B13","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1093\/ECCO-JCC\/JJAC021","article-title":"Identification of gene expression profiles associated with an increased risk of post-operative recurrence in Crohn\u2019s disease","volume":"16","author":"Ngollo","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2025102819160550300_jjaf162-B14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/J.EBIOM.2019.01.027","article-title":"Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease","volume":"40","author":"Verstockt","year":"2019","journal-title":"EBioMedicine"},{"key":"2025102819160550300_jjaf162-B15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/NM.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor\u2013neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med"},{"key":"2025102819160550300_jjaf162-B16","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/APT.15126","article-title":"Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn\u2019s disease","volume":"49","author":"Verstockt","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102819160550300_jjaf162-B17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/apt.14944","article-title":"Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn\u2019s disease: results from a prospective cohort study","volume":"48","author":"Auzolle","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102819160550300_jjaf162-B18","doi-asserted-by":"publisher","first-page":"1008456","DOI":"10.3389\/FIMMU.2022.1008456","article-title":"Autologous organoid co-culture model reveals T cell-driven epithelial cell death in Crohn\u2019s Disease","volume":"13","author":"Hammoudi","year":"2022","journal-title":"Front Immunol"},{"key":"2025102819160550300_jjaf162-B19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3390\/IJMS26010121","article-title":"Key interleukins in inflammatory bowel disease-a review of recent studies","volume":"26","author":"Aebisher","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025102819160550300_jjaf162-B20","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1136\/GUTJNL-2022-328421","article-title":"Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn\u2019s disease highlight earliest events of pathogenesis","volume":"72","author":"Leibovitzh","year":"2023","journal-title":"Gut"},{"key":"2025102819160550300_jjaf162-B21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2174\/187153007780832109","article-title":"CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication","volume":"7","author":"Singh","year":"2007","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2025102819160550300_jjaf162-B22","doi-asserted-by":"publisher","first-page":"e101622","DOI":"10.1371\/JOURNAL.PONE.0101622","article-title":"The role of CXCR3 in DSS-induced colitis","volume":"9","author":"Chami","year":"2014","journal-title":"PLoS One"},{"key":"2025102819160550300_jjaf162-B23","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/ECCO-JCC\/JJAB186","article-title":"A role for CXCR3 ligands as biomarkers of post-operative Crohn\u2019s disease recurrence","volume":"16","author":"Walshe","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2025102819160550300_jjaf162-B24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/J.BIOCEL.2007.11.020","article-title":"Approaching the degradome in idiopathic pulmonary fibrosis","volume":"40","author":"Pardo","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"2025102819160550300_jjaf162-B25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/HEARTJNL-2013-304129","article-title":"The association of genetic variants of matrix metalloproteinases with abdominal aortic aneurysm: a systematic review and meta-analysis","volume":"100","author":"Morris","year":"2014","journal-title":"Heart"},{"key":"2025102819160550300_jjaf162-B26","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/PATH.1978","article-title":"Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium","volume":"209","author":"Kobayashi","year":"2006","journal-title":"J Pathol"},{"key":"2025102819160550300_jjaf162-B27","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/LABINVEST.2012.141","article-title":"Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia","volume":"92","author":"Koller","year":"2012","journal-title":"Lab Invest"},{"key":"2025102819160550300_jjaf162-B28","doi-asserted-by":"publisher","first-page":"e12962","DOI":"10.1111\/SJI.12962","article-title":"Increased expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and MMP10, MMP23 in inflammatory bowel disease: cross-sectional study","volume":"93","author":"Fonseca-Camarillo","year":"2021","journal-title":"Scand J Immunol"},{"key":"2025102819160550300_jjaf162-B29","doi-asserted-by":"publisher","first-page":"964131","DOI":"10.1155\/2015\/964131","article-title":"Matrix metalloproteinases in inflammatory bowel disease: an update","volume":"2015","author":"O\u2019Sullivan","year":"2015","journal-title":"Mediators Inflamm"},{"key":"2025102819160550300_jjaf162-B30","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/ECCO-JCC\/JJAD049","article-title":"Serum immune profiling in paediatric Crohn\u2019s disease demonstrates stronger immune modulation with first-line infliximab than conventional therapy and pre-treatment profiles predict clinical response to both treatments","volume":"17","author":"Jongsma","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2025102819160550300_jjaf162-B31","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/J.CGH.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn\u2019s disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819160550300_jjaf162-B32","doi-asserted-by":"publisher","first-page":"e361\u201379","DOI":"10.1016\/J.CGH.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102819160550300_jjaf162-B33","doi-asserted-by":"publisher","first-page":"jjae169","DOI":"10.1093\/ECCO-JCC\/JJAE169","article-title":"Characterisation of IBD heterogeneity using serum proteomics: a multicentre study","volume":"19","author":"Salomon","year":"2025","journal-title":"J Crohns Colitis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf162\/64222231\/jjaf162.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/9\/jjaf162\/64222231\/jjaf162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/9\/jjaf162\/64222231\/jjaf162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:16:15Z","timestamp":1761693375000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf162\/8249233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf162","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,9]]},"article-number":"jjaf162"}}